His office has been contacted for comment. Watch this space. Brisbane-based needle-free vaccination firm Vaxxas will progress a $7.2m program to develop vaccines to combat diseases including ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, announced that CEPI, the Coalition for Epidemic Preparedness ...

Vaxxas Pty. Ltd. and the Coalition for Epidemic Preparedness Innovations are progressing heat-stable, dried-formulation mRNA vaccines using Vaxxas’ needle-free high-density microarray patch.

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Highlights,Vaxxas,secures $7.2M program approval for needle-free vaccine development.,Technology allows vaccine storage at room temperature for better accessibility.,Collaboration with SK Bioscience ...

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, dried-formulation mRNA vaccines delivered using Vaxxas’ needle-free high-density ...

CEPI has approved the advancement of the vaccine program following promising proof-of-concept results generated by Vaxxas in preclinical models, showing excellent thermostability and effective deliv..